Loading
Cancer Cells and Metastasis / CAR-T Cell Therapy Research / Cancer Research and Treatments · Journal article
Discover Oncology · September 4, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes advances in regenerative medicine approaches—including stem cells, gene therapy, tissue engineering, and nanoparticle platforms—for cancer therapy. It identifies five key unresolved controversies (safety and tumorigenicity of stem cells, TME-versus-tumor-directed strategies, durability of gene delivery, immune activation versus off-target effects, and clinical translation criteria) and provides recommendations for future translational research and trial design.
Journal article. Patients with cancer (implied through cancer therapy context); specific populations not detailed..
Regenerative medicine can augment cancer therapy by leveraging stem cells, gene therapy, and tissue engineering to address limitations of conventional treatments. Five key unresolved controversies are identified: safety and tumorigenicity of stem-cell platforms; optimal TME-versus-tumor-directed strategies; durability and scalability of gene-delivery systems; balancing immune activation with off-target inflammation; and criteria for clinical translation and patient selection.
Five key unresolved controversies are identified: safety and tumorigenicity of stem-cell platforms; optimal TME-versus-tumor-directed strategies; durability and scalability of gene-delivery systems; balancing immune activation with off-target inflammation; and criteria for clinical translation and patient selection.
Clinicians and researchers should use this review to understand the current landscape of regenerative oncology approaches, the key scientific uncertainties that remain unresolved, and recommended priorities for future translational and clinical work.
A narrative review synthesizing recent advances in regenerative medicine for cancer therapy, identifying unresolved controversies and providing recommendations for translational research and trial design, but not reporting original research data or clinical outcomes.
Clinicians and researchers should use this review to understand the current landscape of regenerative oncology approaches, the key scientific uncertainties that remain unresolved, and recommended priorities for future translational and clinical work.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Regenerative medicine has emerged as a transformative field that can augment cancer therapy by leveraging stem cells, gene therapy, and tissue engineering to address limitations of conventional treatments. This review synthesizes recent advances in cell-based therapies, biomaterial scaffolds, gene-delivery systems, and nanoparticle platforms, and it organizes key unresolved controversies that shape research priorities: safety and tumorigenicity of stem-cell platforms; optimal TME-versus-tumor-directed strategies; durability and scalability of gene-delivery systems; balancing immune activation with off-target inflammation; and criteria for clinical translation and patient selection. We summarize updated clinical outcome data where relevant and provide recommendations to guide translational research and trial design toward safer, durable, and personalized regenerative oncology approaches.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.